AMT-143 / AmacaThera - LARVOL DELTA

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain (PRNewswire) - "AmacaThera Inc...has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management."

Trial status • Pain

AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials (Businesswire) - "AmacaThera...announced today that it has completed an oversubscribed US$10.3 million Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion...AmacaThera’s lead product, AMT-143, is being developed for the treatment of post-surgical pain..."

Financing • Pain